Original Article
Copyright ©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Jun 28, 2012; 18(24): 3089-3098
Published online Jun 28, 2012. doi: 10.3748/wjg.v18.i24.3089
Table 1 Patient characteristics
CharacteristicsG + E group (n = 31)G group (n = 30)P
Age (yr)50.7 ± 1.846.9 ± 1.50.4161
Gender (male/female)4/278/220.2112
Hepatitis history (yes/no)5/266/240.7492
AFP ( ≤ 20 ng/mL/> 20 ng/mL)13/1814/160.7992
Liver cirrhosis (Yes/no)10/217/230.5702
ALT ( ≤ 40 U/L/> 40 U/L)18/1311/190.7952
Child-Pugh Score (A/B)2/292/281.0002
Tumor differentiation (I-II/III-IV)7/249/210.5702
Tumor size ( ≤ 5 cm/> 5 cm)8/237/231.0002
Tumor number (single/multiple)8/235/250.5342
Tumor encapsulation (complete/none)12/1915/150.4442
Vascular invasion (no/yes)6/258/220.5542
Blood loss ( ≤ 200 mL/> 200 mL)1/304/260.1952
Anesthesia time ( ≤ 3 h/> 3 h)18/139/210.4262
VAS score3.58 ± 0.323.67 ± 0.380.8631
Dose of fentanyl (μg)0.30 ± 0.010.51 ± 0.01< 0.0011
Dose of morphine (mg)2.26 ± 0.0895.30 ± 1.17< 0.0011
Dose of sevoflurane (mL)21.74 ± 0.7037.90 ± 1.60< 0.0011
Table 2 T-helper 1, T-helper 2, T-helper 17 and regulatory T cell frequencies in patients
Variablesd0 (%)d2 (%)d7 (%)P (d0/d2)P (d0/d7)P (d2/d7)
Th17.21 ± 1.0118.82 ± 1.9313.40 ± 0.79< 0.001< 0.0010.015
Th21.12 ± 0.093.32 ± 0.310.93 ± 0.10< 0.0010.180< 0.001
Th172.57 ± 0.222.95 ± 0.261.23 ± 0.100.269< 0.001< 0.001
Treg6.02 ± 0.276.93 ± 0.385.45 ± 0.520.1600.3290.021
Th1/Th28.12 ± 1.248.50 ± 1.1414.87 ± 1.260.823< 0.001< 0.001
Table 3 Comparison of T-helper 1, T-helper 2, T-helper 17, regulatory T cell frequencies and T-helper 1/T-helper 2 cell ratio between G + E and G anesthesia groups
VariablesG + E group (%)G group (%)P
Th1
d07.44 ± 1.547.38 ± 1.350.87
d214.66 ± 1.9620.42 ± 2.770.098
d716.57 ± 0.9610.37 ± 0.84< 0.001
Th2
d01.08 ± 0.141.14 ± 0.120.745
d22.64 ± 0.303.98 ± 0.490.028
d70.73 ± 0.071.14 ± 0.170.231
Th17
d02.80 ± 0.262.65 ± 0.360.424
d22.56 ± 0.303.01 ± 0.380.374
d71.08 ± 0.101.45 ± 0.150.047
Treg
d05.44 ± 0.266.62 ± 0.450.372
d27.42 ± 0.606.43 ± 0.460.194
d74.51 ± 0.566.19 ± 0.800.003
Th1/Th2 ratio
d08.63 ± 1.767.62 ± 1.320.688
d29.67 ± 1.947.40 ± 1.260.253
d714.64 ± 0.566.03 ± 0.83< 0.001
Table 4 Comparison of interferon-γ, interleukin-4, interleukin-17, FoxP3 mRNA levels and interferon-γ/interleukin-4 mRNA ratio between G + E and G groups
VariablesG + E group (×105)G group (×105)P
IFN-γ
d021.84 ± 2.9916.49 ± 0.840.585
d250.91 ± 1.4662.87 ± 2.710.096
d741.05 ± 1.0529.36 ± 0.730.029
IL-4
d047.12 ± 28.6559.97 ± 15.170.651
d266.63 ± 18.45110.12 ± 24.11< 0.001
d731.80 ± 14.5958.21 ± 5.740.224
IL-17
d0351.29 ± 55.29386.64 ± 61.880.768
d2406.68 ± 68.21677.80 ± 133.070.171
d7226.20 ± 18.37429.94 ± 11.900.042
FoxP3
d0430.38 ± 48.95384.52 ± 42.190.408
d2468.85 ± 89.81432.97 ± 44.450.338
d7248.68 ± 58.71361.01 ± 46.750.109
IFN-γ/IL-4 ratio
d00.44 ± 0.030.39 ± 0.040.883
d20.80 ± 0.100.58 ± 0.030.198
d71.14 ± 0.080.56 ± 0.010.003
Table 5 Plasma interferon-γ, interleukin-4, interleukin-17, interleukin-10, transforming growth factor-β1 concentrations between G + E and G groups
VariablesG + E group (pg/mL)G group (pg/mL)P
IFN-γ
d07.56 ± 0.446.67 ± 0.700.653
d211.17 ± 0.9719.94 ± 1.370.018
d78.67 ± 0.745.76 ± 0.530.165
IL-4
d010.31 ± 1.7810.53 ± 1.280.892
d221.11 ± 3.7636.69 ± 6.970.013
d713.00 ± 1.8825.50 ± 2.980.065
IL-17
d020.26 ± 5.8218.83 ± 3.950.304
d227.26 ± 10.3040.10 ± 10.560.239
d79.12 ± 1.6716.66 ± 2.380.009
IL-10
d03.67 ± 0.353.37 ± 0.310.528
d27.17 ± 0.865.97 ± 0.480.218
d74.09 ± 0.295.65 ± 0.720.06
TGF-β1
d06565 ± 16675312 ± 11020.539
d215680 ± 42548375 ± 13950.12
d77555 ± 155510691 ± 25710.311
IFN-γ/ IL-4
d00.74 ± 0.100.65 ± 0.130.618
d20.67 ± 0.080.56 ± 0.050.309
d71.10 ± 0.140.35 ± 0.08< 0.001